Navigation Links
Lexicon Announces Proposed $95 Million Common Stock Offering
Date:3/8/2010

t);s.linkTrackVars='prop5,eVar3,prop15';s.prop5='External Link';s.eVar3=s.prop5;s.prop15='86832442';s.tl(this,'o','ExternalLink');" target='_blank' href="http://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww.sec.gov&esheet=6002071&lan=en_US&anchor=www.sec.gov&index=1">www.sec.gov.  Alternatively, you may obtain a preliminary prospectus supplement and accompanying prospectus as indicated above.

About Lexicon

Lexicon is a biopharmaceutical company focused on discovering breakthrough treatments for human disease.  Lexicon currently has five drug candidates in development for autoimmune disease, carcinoid syndrome, diabetes, glaucoma and irritable bowel syndrome, all of which were discovered by the company's research team.  

Safe Harbor Statement

This press release contains "forward-looking" statements, including statements related to Lexicon's expectations regarding the completion, timing and size of the proposed public offering. Any statements contained in this press release that are not statements of historical fact may be deemed to be forward-looking statements. &#
'/>"/>

SOURCE Lexicon Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Lexicon to Report Fourth Quarter and Year End 2009 Financial Results on February 23, 2010
2. Lexicon Pharmaceuticals to Present at the 12th Annual BIO CEO & Investor Conference
3. Lexicon to Host Conference Call and Webcast to Review Top-Line Phase 2 Results From Diabetes Trial
4. Lexicon to Present Positive Top-Line Phase 2 Results for LX1031 in Non-Constipating Irritable Bowel Syndrome at GASTRO 2009
5. Lexicon Announces Positive Phase 2 Results of LX1031 in Non-Constipating Irritable Bowel Syndrome
6. Lexicon Announces Completion of Public Offering of Common Stock
7. Lexicon Announces Pricing of Common Stock in Public Offering
8. Lexicon Completes Phase 1 Clinical Trial and Initiates Phase 2 Clinical Trial of LX4211 in Patients With Type 2 Diabetes
9. Lexicons Drug Candidate LX1032 for Carcinoid Syndrome Receives Orphan Drug Designation From EMEA
10. Lexicon Pharmaceuticals Provides Clinical Pipeline Update and Reports 2009 First Quarter Results
11. Lexicon Presents Clinical Data on LX1032 for Carcinoid Syndrome at European Neuroendocrine Tumor Society Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/29/2015)... , June 29, 2015  New guidelines ... American Stroke Association give hope for better outcomes ... experience an acute ischemic stroke each year. Stryker,s ... key products used in the clinical trials that ... new AHA/ASA guidelines strongly recommend endovascular therapy with ...
(Date:6/29/2015)... 2015  Nevro Corp. (NYSE: NVRO ), a ... solutions for the treatment of chronic pain, today announced ... Officer of Intersect ENT (NASDAQ: XENT ), has ... 28, 2015. For the last seven ... ENT, a company dedicated to improving the quality of ...
(Date:6/29/2015)... ZIONA, Israel , June ... (Nasdaq: BVXV, TASE: BVXV) today announced positive preliminary results ... BiondVax,s candidate for a universal influenza vaccine. In this ... ages of 50 to 65, followed by an administration ... weeks later. M-001 was found to be safe and ...
Breaking Medicine Technology:New AHA Guidelines For The Early Management And Treatment Of Stroke Will Change The Standard Of Care For Thousands Of Stroke Patients Each Year 2New AHA Guidelines For The Early Management And Treatment Of Stroke Will Change The Standard Of Care For Thousands Of Stroke Patients Each Year 3Nevro Appoints Lisa Earnhardt to its Board of Directors 2BiondVax Presents BVX-006 Preliminary Phase II Results: the Universal Flu Vaccine at Higher Doses is Safe and Improves Immunogenicity in Older Adults 2BiondVax Presents BVX-006 Preliminary Phase II Results: the Universal Flu Vaccine at Higher Doses is Safe and Improves Immunogenicity in Older Adults 3
... 2011 /PRNewswire-Asia/ -- Pharmaceutical company Hatchtech Pty Ltd has ... study to confirm the efficacy of its novel head ... is evaluating the efficacy, safety and tolerability of two ... to vehicle. The trial consists of treating 132 healthy ...
... Aug. 31, 2011 Onyx Pharmaceuticals, Inc. (Nasdaq: ... appointed Helen Torley, M.B. Ch. B., M.R.C.P.,  as Executive ... Dr. Torley will report to N. Anthony Coles, M.D., ... for all commercial activities related to Nexavar and the ...
Cached Medicine Technology:Hatchtech Completes Treatment Phase of 2b Clinical Trial of New-Generation Head Lice Treatment Deovo™ 2Hatchtech Completes Treatment Phase of 2b Clinical Trial of New-Generation Head Lice Treatment Deovo™ 3Onyx Pharmaceuticals Appoints Dr. Helen Torley as Chief Commercial Officer 2Onyx Pharmaceuticals Appoints Dr. Helen Torley as Chief Commercial Officer 3
(Date:6/30/2015)... ... June 30, 2015 , ... Rocky Mountain Oils, a leading non-MLM supplier ... added a new CEO, Mr. Darold Francis. The changes will help enhance the company’s ... that customers have come to know and respect for over eight years. , “I ...
(Date:6/30/2015)... ... June 30, 2015 , ... ... manager of HRA Healthcare Research & Analytics , a consultative healthcare market ... Inc. (MJH) family of businesses. HRA offers quantitative and qualitative, custom and multi-client ...
(Date:6/30/2015)... Los Angeles, CA (PRWEB) , ... June 30, ... ... Physicians News Digest discussed the advantages that fat transfer procedures had ... breast reconstruction using fat transfer techniques create breasts that “look and feel natural,” ...
(Date:6/30/2015)... ... June 30, 2015 , ... Board certified otolaryngologist Dr. Marcelo ... . , Dr. Antunes is a fellowship trained facial plastic ... In addition to performing cosmetic and reconstructive surgery on the face, he enjoys ...
(Date:6/30/2015)... ... ... James C. Wittig, MD , Vice Chairman of ... of the Skin and Sarcoma division at the John Theurer Cancer Center is ... Pathology Course. The newly installed lectures are designed to education patients, students, ...
Breaking Medicine News(10 mins):Health News:Rocky Mountain Oils Adds New CEO, Announces Relocation of Operations to Orem, Utah 2Health News:HRA Healthcare Research & Analytics Welcomes 'Creative Problem Solver' as New Executive Vice President 2Health News:HRA Healthcare Research & Analytics Welcomes 'Creative Problem Solver' as New Executive Vice President 3Health News:Recent Article Advocating for Breast Reconstruction with Fat Transfers Successfully Outlines the Advantages of Transfer Procedures, Notes Beverly Hills Physicians 2Health News:Recent Article Advocating for Breast Reconstruction with Fat Transfers Successfully Outlines the Advantages of Transfer Procedures, Notes Beverly Hills Physicians 3Health News:Atlanta Otolaryngologist Dr. Marcelo Antunes Joins Northwest ENT and Allergy Center 2Health News:Atlanta Otolaryngologist Dr. Marcelo Antunes Joins Northwest ENT and Allergy Center 3Health News:NJ Top Doc, Dr. James C. Wittig, has Enhanced his Education Portal on TumorSurgery.org 2Health News:NJ Top Doc, Dr. James C. Wittig, has Enhanced his Education Portal on TumorSurgery.org 3
... New research found only 45 percent of players return to same or higher ... ... percent of baseball,players were able to return to the game at the same ... during,the 2008 American Orthopaedic Society for Sports Medicine Specialty Day at,The Moscone Center., ...
... The Associated Press will,publish a series of ... of pharmaceuticals in drinking water. While the issue ... not new, the series,may prompt concern among consumers. ... Works Association (AWWA), issued the following,statement:, "The ...
... - AstraZeneca and Bristol-Myers Squib - not part of ... ... Today eleven major pharmaceutical,companies, including Abbott Laboratories (NYSE: ABT ... million nationwide settlement,in the average wholesale price (AWP) litigation filed in ...
... March 7 The following statement is,from Hughes Hubbard ... LLP:, United States District Judge Eldon E. Fallon ... Deputy Special Masters who will decide,any appeals taken from ... program for Vioxx product liability litigation in the,United States, ...
... for,International Development and USAID Administrator Henrietta Fore hosted,Mrs. ... Women,s Day,celebration today. The internationally recognized day is ... the world and inspire all,women to achieve their ... reminder,of the continued action that is required to ...
... named 13 translational researchers as the 2008 recipients ... The awards, which provide $150,000 per year ... established, independent physician-scientists who are dedicated to translational ... treatmentand mentoring physician-scientist trainees. , The award ...
Cached Medicine News:Health News:Comeback to a Pre-Injury Level After Elbow or Shoulder Surgery Disappointing for Pro Baseball Players 2Health News:Hagens Berman: Eleven Defendants Settle in Average Wholesale Price Litigation 2Health News:Hagens Berman: Eleven Defendants Settle in Average Wholesale Price Litigation 3Health News:Special Masters Appointed in Program to Resolve U.S. VIOXX(R) Product Liability Lawsuits 2Health News:Special Masters Appointed in Program to Resolve U.S. VIOXX(R) Product Liability Lawsuits 3Health News:Special Masters Appointed in Program to Resolve U.S. VIOXX(R) Product Liability Lawsuits 4Health News:First Lady Honors Women at International Women's Day Event 2Health News:Burroughs Wellcome Fund grants $9.75 million towards translational researchers 2
Medtronic Ophthalmics offers a comprehensive selection of corneal trephine,blades and handles. Handcrafted, sharp, uniform blade edges promote a,symetrical and vertical cut of all corneal layers....
Medtronic Ophthalmics offers a comprehensive selection of corneal trephine,blades and handles. Handcrafted, sharp, uniform blade edges promote a,symetrical and vertical cut of all corneal layers....
Medtronic Ophthalmics offers a comprehensive selection of corneal trephine,blades and handles. Handcrafted, sharp, uniform blade edges promote a,symetrical and vertical cut of all corneal layers....
Each handle is designed to fit a specific trephine size....
Medicine Products: